Artelo Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Gregory D. Gorgas
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 505 Lomas Santa Fe Solana Beach CA United States of America 92075
- IPO Date
- Jun 21, 2019
- CIK
- 0001621221
- Website
- artelobio.com
- Similar Companies
- Business
- Artelo Biosciences, Inc. (Nasdaq: ARTL) is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, to address unmet needs in cancer, pain, inflammation, anxiety, dermatologic conditions and anorexia. The company's core product candidates include ART27.13, a synthetic CB1/CB2 receptor agonist in Phase 2 for cancer-related anorexia and weight loss via the CAReS study; ART26.12, a FABP5 inhibitor advancing toward clinical trials for chemotherapy-induced peripheral neuropathy and pain; and ART12.11, a synthetic CBD cocrystal in preclinical development for inflammatory bowel disease, anxiety, depression, epilepsy and insomnia. Founded in 2011 and headquartered in Solana Beach, California, with additional operations in La Jolla, California; Alderley Edge, United Kingdom; and Dublin, Ireland, Artelo targets oncology supportive care, neurology and dermatology markets primarily in the United States and Europe. Recent developments include a $3 million funding round in September 2025 to support Phase 2 data release for ART27.13 and initiation of a multiple ascending dose study for ART26.12; a $1.425 million at-the-market private placement in June 2025 to fund clinical data releases and R&D operations through late 2026, including a strategic $250,000 investment in SOL cryptocurrency for data infrastructure; completion of Phase 1b/2a trials for ART27.13 as of late 2024; and ongoing preclinical advancement of ART26.12 with data presentations.
Company News
Artelo Biosciences, Inc. (NASDAQ:ARTL) Stock Short Interest Rises 104.7%
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Artelo Biosciences, Inc. (NASDAQ:ARTL) Shares Shorted: Short Interest Down 37.2% in September
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Down 36.9% in August
Artelo Biosciences Announces Reverse Stock Split
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development